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Abstract 
AIM: To identify new markers of hepatocellular carci-
noma (HCC) using a proteomic analysis. 
METHODS: Patients with liver cirrhosis of the three 
most frequent etiologies: hepatitis C virus, hepatitis B 
virus and alcoholic liver disease, were included in the 
study. The samples were analysed by 2D-electrophoresis 
in order to determine the differential protein expression. 
The proteins were separated according to the charge in 
immobilized pH 3-10 gradient strips and then by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. Prot-
eins of interest were excised, digested with trypsin and 
the resulting peptides were separated and identified.
RESULTS: Three differentially expressed apolipoproteins 
(Apo) were identified based on the protein profile using 
proteomic techniques: Apo-A1, Apo-A4 and Apo-E. 
Apo-A4 levels were significantly lower in HCC than in 
non-HCC patients regardless of etiology (P  < 0.01). 
Multivariate logistic regression showed that Apo-A4 
and Apo-A1 were the only independent factors related 
to HCC diagnosis (P  < 0.05). The receiver operating 
characteristic (ROC) curve including both Apo-A4 and 
Apo-A1 showed an area under the ROC of 0.944 (P  < 
0.001), a sensitivity of 0.89 and a specificity of 0.81 for 
diagnosis of HCC. 
CONCLUSION: Apo-A4 and Apo-A1 may be used 
clinically as biomarkers of HCC with a high sensibility 
and specificity. These findings may provide additional 
insights into the mechanism of HCC development and 
progression. 
Key words: Liver cancer; Apolipoproteins; Serum bio-
markers; 2D polyacrylamide gel electrophoresis; Mass 
spectrometry
Peer reviewer: Ajith T A, PhD, Assistant Professor of Bio-
chemistry, Department of Biochemistry, Amala Institute of 
Medical Sciences, Amala Nagar, Thrissur 680555, India
Pleguezuelo M, Lopez-Sanchez LM, Rodriguez-Ariza A, 
Montero JL, Briceno J, Ciria R, Muntane J, de la Mata M. 
Proteomic analysis for developing new biomarkers of hepato-
cellular carcinoma. World J Hepatol 2010; 2(3): 127-135 
Available from: URL: http://www.wjgnet.com/1948-5182/full/
v2/i3/127.htm  DOI: http://dx.doi.org/10.4254/wjh.v2.i3.127
INTRODUCTION
Hepatocellular carcinoma (HCC) is the 6th cancer in 
incidence worldwide and the 3rd leading cause of  cancer 
death. Overall, the survival of  patients diagnosed with 
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HCC remains very poor, with 1-year and 3-year survival 
rates of  36% and 17%, respectively[1]. The high mortality 
associated with HCC is primarily because by the time it 
is diagnosed, it is often unresponsive to treatment. Only 
12% of  cases receive potentially curative therapy (rese-
ction or transplantation).
Major common risk factors of  HCC include hepatitis 
C virus (HCV), hepatitis B virus (HBV) and alcoholic liver 
disease (ALD). Rare risk factors include hemochromatosis, 
α1 anti-trypsin deficiency, and Wil­son's disease. HBV or 
HCV infection is responsible for at least 80% of  all HCC. 
With increase of  HCV infection and immigration from 
HBV endemic populations, the number of  deaths due 
to HCC in the United States is expected to rise over the 
next 20 years[2]. Most HCC cases develop in patients with 
advanced chronic liver disease; the increase in the number 
of  patients living with cirrhosis may be another cause of  
the increased incidence of  HCC. Therefore, methods to 
improve early detection and diagnosis of  HCC as well 
as stratification of  prognosis would be of  great clinical 
benefit. 
Although HCC meets the criteria of  a tumor that 
w­oul­d benefit from surveil­l­ance programs, the poor sen-
sitivity and specificity of  currently available tools have 
hindered their implementation. Ultrasound is particularly 
subject to l­ow­ sensitivity and specificity w­hen appl­ied to 
cirrhotic patients and depends on the skills of  ultraso-
nographist. Due to its high incidence and poor prognosis 
when diagnosed at a symptomatic stage, early HCC diag-
nosis has become a priority nowadays.
The outcome of  HCC patients still remains dismal 
due to the difficul­ty in detecting the disease at its earl­y 
stage, partly because of  our limited knowledge of  the 
molecular pathogenesis. There is a need to search for 
more serologic markers that are specifically associated 
with HCC, especially in the presence of  cirrhosis. Ther-
efore, studies aimed to improve the knowledge of  the 
mechanisms associated with HCC development and to 
identify new biomarkers are urgently needed for its early 
diagnosis and the application of  more effective thera-
peutic interventions[3]. 
Hepatocarcinogenesis is a slow multistep and multi-
factorial process, usually the consequence of  long-term 
inflammation and fibrosis, w­hich invol­ves the accumu-
lation of  changes in the genome. At early stages, these 
alterations lead to the disruption of  several genes that 
act in different regulatory pathways. The accumulation 
of  irreversible structural alterations in genes and chro-
mosomes result in the development of  dysplastic hepato-
cytes, nodules and eventually HCC[4]. 
Therefore, the application of  new technologies to im-
prove our knowledge about the molecular pathogenesis 
of  HCC, to identify biomarkers leading to an early dia-
gnosis, and to define new­ therapeutic targets, is of  great 
interest. Biomarkers are defined as indicators of  genetic, 
cellular, biochemical or molecular alterations which can 
distinguish normal from abnormal biological processes. 
The ideal­ biomarker for HCC must be specific, traceabl­e 
at a very early stage and not detectable in pre-malignant 
hepatic disease. With recent advances in genomics 
and proteomics, a great number of  potential markers 
have been identified and developed as new candidate 
markers for HCC. Tumor markers may be useful for the 
detection of  HCC in early stages, and also may provide 
information about its prognosis. Their use might be 
extended to therapeutic assessment and detection of  
recurrence[5]. 
There are different strategies for searching tumor ma-
rkers. One is based on direct analysis of  serum or other 
biological fluid, the other one is based on analysis of  
the tissue[6]. However, it is a challenging task due to the 
complexity of  the proteome. Hundreds of  thousands of  
different protein species present in the biol­ogical­ fluid or 
tissues must be separated, identified, and characterized, 
and it cannot be fully accomplished by a single exper-
imental approach[3]. 
Although alpha fetoprotein (AFP) has been the 
most widely used marker for HCC, its sensitivity and 
specificity are poor[7] and the false-negative or positive 
rate with AFP level alone can reach 40%, especially for 
early HCC (< 3 cm in diameter). Its positive predictive 
value depends on the cut-off  value, ethnicity, treatment 
and tumor stage. Its sensitivity and specificity for HCC 
diagnosis are 41%-65% and 80%-94%, respectively with 
a cut-off  of  20 ng/mL[8]. A fucosylated variant of  the 
AFP gl­ycoprotein (AFP-L3) has show­n better specificity 
than AFP for HCC diagnosis (63%-91.6%), but similar 
sensitivity (36%-71%)[9,10]. However, its specificity is 
limited, since its concentration can also increase in non-
tumor, extrahepatic diseases such as diabetes, pancreatitis 
and hypothyroidism. 
Although other numerous biomarkers with potential 
diagnostic or prognostic significance for HCC have been 
identified, most of  them are considered non-specific as 
they can also be abnormally expressed in patients with 
non-malignant liver diseases. Furthermore, some of  them 
have never reached general use due to lack of  reagents, 
reproducibility and a good and clear system of  develop-
ment[11]. There have been only two FDA-approved tumor 
markers until now (AFP and AFP-L3). Therefore, a stand-
ardized approach is required to assess the tumor markers, 
and validation in large patient cohorts and preferably from 
multiple centres is necessary.
Proteins perform and regulate most biological fun-
ctions. The systematic analysis of  the whole proteome 
(proteinic complement of  cells) may provide a functional 
meaning to the information provided by genome ex-
pression studies. Expression of  proteins or their isoforms 
can be detected by proteomic analysis, and it also allows 
the detection of  post-translational modifications. These 
data provide us with precious information to understand 
the molecular basis of  HCC and to follow the course of  
the disease. Eventually, it could lead to earlier diagnosis 
of  HCC that is essential in determining the best course 
of  treatment options and possible outcomes. The plasma 
is an excellent target for proteomic approaches since it 
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is readily available from patients on a regular basis and it 
is in contact with all tissues in the body, thus may reveal 
differences in the proteins expressed in these tissues. The 
new techniques for proteomic analysis allow several strate-
gies for the identification of  marker proteins for HCC. 
One of  the most common applications of  proteomics 
is the development of  novel biomarkers of  disease, par-
ticularly cancer. A challenge for successful biomarker 
identification is to obtain appropriate samples. In spite 
of  many recent technological advances in methods for 
the separation and analysis of  proteins, two-dimensional 
gel electrophoresis (2DGE) is still the ‘‘gold standard’’ 
technique in this area[12]. This technique allows the sep-
aration of  thousand proteins on the basis of  both size 
and charge from a tissue or biological fluid. The high-
resolution study of  proteins by 2DGE is performed using 
immobil­ized pH gradients (IPG) in gel­s; this approach 
provides better resolution, reproducibility and loading 
capacity. The high potential of  2DGE on biomarker 
discovery is related to its ability to get information from 
the separated protein spots. Thus, in-gel digestion of  pro-
teins w­ith specific endoproteases such as trypsin, enabl­es 
us to obtain protein fingerprints, w­hich can be anal­yzed 
by Matrix-assisted l­aser desorption / ionization time-
of-flight mass spectrometry (MALDI-TOF). A protein 
spot can be identified by comparison of  the mass spectro-
metric peptide map with that theoretically calculated in a 
database. 
This study was aimed to identify potential biomarkers 
of  HCC in patients with cirrhosis. Plasma samples from 
patients with cirrhosis and HCC were compared with 
those from patients with cirrhosis but without HCC. 
Proteomic anal­ysis w­as performed to compare the profil­e 
of  protein expression. We hypothesize that those markers 
may be useful for the diagnosis of  HCC. 
MATERIALS AND METHODS
Patients with liver cirrhosis of  the three most frequent 
aetiologies currently (HBV, HCV and ALD) were included 
in the study. Those patients w­ere cl­assified into tw­o groups 
on the basis of  the diagnosis of  HCC. Histopathological 
cl­assification for cirrhosis w­as performed according to the 
Ishak grading system[13]. HCC diagnosis was established 
according to the Barcelona-2000 criteria[7]. Written consent 
was obtained from each patient in the study and approval 
from Institutional Review Board. 
The sampl­es w­ere anal­yzed by 2D-el­ectrophoresis in 
order to determine the differential protein expression. The 
proteins were separated according to the charge in imm-
obil­ized pH 3-10 gradient strips and then by sodium dodecyl­ 
sulfate polyacrylamide gel electrophoresis (SDS PAGE). Pro-
teins of  interest were excised, digested with trypsin and the 
resul­ting peptides w­ere separated and identified. The protein 
expression profil­e of  patients w­ith HCC w­as compared w­ith 
that of  patients w­ithout HCC for the identification of  poten-
tial circulating biomarkers of  HCC. 
Sample preparation
Peripheral blood samples (4.0 mL) were collected in sterile 
tubes containing 5.4 mg EDTA. Blood was immediately 
cooled on ice and within 15 min centrifuged at 3000 xg 
for 10 min to separate the plasma which was aliquoted 
and stored at -80℃.  
The plasma was depleted of  high abundant proteins 
using the ProteoPrepTM kit (Sigma-Al­drich). This affinity 
chromatography removes the 20 most abundant proteins 
in plasma, effectively enriching the other plasma proteins 
and maximizing their resol­ution by el­ectrophoresis. Prot-
ein concentration of  the depleted plasma was estimated 
with the Bradford assay using bovine serum albumin as 
standard.
2D-electrophoresis
2D gel electrophoresis was performed on selected samples 
using IPG strips (3-10 pH range, Biorad). Briefly, 1 mg 
plasma protein was mixed with 300 µL sample buffer (7 
mol/L urea, 2mol/L thiourea, 4% CHAPS, 20mmol/L 
DTT, 0.5% TRITONx-100, 0.5% pharmalyte 3-10 and 
0.001% blue bromophenol) and rehydrated into IPG stri-
ps overnight. 
Isoelectric focusing was carried out for 34 000 VHs 
using a PROTEAN IEF system (BioRad). The IPG strips 
were then soaked into equilibration buffer (50mmol/L 
Tris-HCL, pH 8.8, 6 mol/L urea, 30% glycerol, 2% SDS 
and 0.001% bromophenol blue), containing 7.5 mg/mL 
DTT for 15 min. Thereafter, they were soaked into equilib-
ration buffer containing 45 mg/mL iodoacetamide for 15 
min. Second dimension was carried out in 12% polyacry-
lamide gel at 35 mA/gel (PROTEAN Xi Cell, BioRad). 
Protein identification
The gel­s w­ere stained w­ith fluorescent dye (SYPRO Ruby, 
BioRad) according to the instruction of  the manufacturer. 
Subsequently, the gels were imaged using LAS3000 (Fuji 
photo fil­m) and anal­yzed w­ith 2D PDQuest softw­are 
(BioRad). To accurately compare the spots between gels, 
image spot intensity w­as normal­ized dividing the raw­ 
intensity of  each spot in a gel by the total intensity of  all 
the valid spots in that gel. 
Protein spots of  interest were excised from the poly-
acrylamide gels using a robotic workstation (Investigatore 
Propice, Genomics Solutions, Ann Arbor, MI, USA) and 
were trypsin-digested using a robotic digestion system 
(ProGeste, Genomic Solutions). Finally, peptides were 
anal­yzed on a MALDI-ToF/ToF 4700 Proteomics Anal­y-
zer (Appl­ied Biosystems, Foster City, CA, USA). Mass 
spectrometry data were searched against the human prot-
ein database from MSDB (mass spectrometry protein 
sequence DataBase), using Mascot search engine (Matrix 
Science Inc., Boston, MA, USA).  
Confirmation of the identified proteins
Protein w­as confirmed using either Western Bl­ot or neph-
el­ometry. For the Western Bl­ot, the proteins separated by 
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2D-el­ectrophoresis w­ere immobil­ized on a nitrocel­l­ul­ose 
membrane using the semidry transfer system Transblot 
(BioRad). Subsequently, the proteins were detected using 
a primary pol­ycl­onal­ antibody (Santa Cruz Biotechnol­ogy 
diluted 1:200 and Chemicon International diluted 1:1 000) 
and the ECL Advance detection system (Amersham Bios-
ciences, Uppsala, Sweden).
Statistical analysis
Demographical and clinical data were evaluated for all 
the patients. Differences between patients with and wi-
thout HCC were assessed by univariate analysis using 
Chi-square tests for categorical variables and t tests for 
continuous variables. In the multivariate analysis, Odds 
ratios (OR) and 95% confidence interval­s (CI) as w­el­l­ as 
P values were calculated for each risk factor. The P value 
≤ 0.05 w­as considered statistical­l­y significant.
Statistical analysis was carried out using Statistical 
Package for Social­ Sciences (SPSS) 12.0 for Window­s 
(release 12.0 SPSS Chicago, IL). 
RESULTS
From January 2005 to January 2006, 22 consecutive pa-
tients with cirrhosis and 18 consecutive patients with 
HCC, were recruited from the outpatient clinic for liver 
diseases at the Reina Sofia University Hospital­ (Cordoba, 
Spain). The characteristics of  the patients are shown in 
Table 1. Most of  them were male, with a mean age of  
56 years. HCV was the most frequent etiological factor 
of  cirrhosis. Univariate analysis comparing patients 
with and without HCC (Table 2) showed that they were 
similar except for Child-Pugh score (5.6 ± 0.9 in HCC 
group vs 10 ± 3.2 in non-HCC group, P = 0.01) and 
INR (1.2 ± 0.1 in HCC patients vs 1.4 ± 0.3 in non-HCC 
patients, P = 0.04). Interestingly, AFP levels in patients 
with HCC were not significantly different from those 
without HCC (14.7 ± 15.8 vs 698.4 ± 1391.1; P = 0.13). 
In patients with HCC, the mean number of  nodules was 
1.7 (range 1-4), incl­uding 33% mul­tinodul­es. The size 
of  principal nodules ranged from 10 to 50 mm (mean 
34.7 mm). There was no macrovascular invasion and 
extrahepatic spread in all cases. 
Proteomic analysis of  the plasma samples and the 
comparison between patients with and without HCC 
revealed differential expression of  8 spots (Figure 1). 
These spots w­ere identified as 3 different apol­ipoproteins:
apolipoproteins (Apo-A1, Apo-A4 and Apo-E). Levels of  
Apo-A4 w­ere significantl­y higher in patients w­ithout HCC 
than in patients with HCC (2.1 ± 0.4 vs 1.4 ± 0.5; P < 0.01) 
(Figure 2). 
We performed a mul­tivariate anal­ysis in w­hich HCC 
diagnosis was the dependent variable (all variables are 
shown in Table 2) and Apos levels were independent 
variables. Logistic multivariate regression revealed that 
levels of  Apo-A1 (OR 1.45; 95% CI: 1.11-1.89, P = 
0.006) and Apo-A4 (OR 0.21; 95% CI: 0.09-0.50, P < 
0.001) were the only factors independently associated 
with HCC. Interestingly, Apo-A1 was associated with an 
elevated risk of  HCC where as Apo-A4 was associated 
with lower risk of  HCC; and AFP was not associated 
with risk of  HCC. From these data the resulting logistic 
equation is:
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Table 1  Demographical and clinical data of the patients
  n  = 40 n  (%) Mean/median SD/range
Gender
   Male    29 (72.5)
   Female    11 (27.5)
Age 55.6 9.5
Etiology of cirrhosis
   HBV 10 (25)
   HCV 16 (40)
   ALD 14 (35)
Child-Pugh  5.5 (5-10)
SD: Standard deviation; HBV: Hepatitis B virus; HCV: Hepatitis C virus; 
ALD: Alcoholic liver disease; HCC: Hepatocellular carcinoma.
Table 2  Comparison of demographic and clinical data 
between patients with and without HCC
NO HCC HCC P
Male 72.70% 72.20% 0.97
Age (yrs) 54.6 ± 10.1 56.8 ± 8.7 0.46
Etiology of cirrhosis
   HBV 22.70% 27.80% 0.69
   HCV 36.40% 44.40% 0.69
   ALD 40.90% 27.80% 0.69
Child-Pugh  10 ± 3.2 5.6 ± 0.9 0.01
HBV-DNA 81.2 ± 94.8    146 ± 206.4 0.56
HCV viral load 1.8 × 106 ± 2.9 × 106 6.1 × 106 ± 4.2 × 106 0.28
ALT 53.9 ± 66.1 83.5 ± 95.7 0.39
AST   86.7 ± 111.1 92.2 ± 80.6 0.89
Bilirubin 3.4 ± 2.9 3.1 ± 3.6 0.81
GGT 69.5 ± 38.8 156.1 ± 159.6 0.09
AP  156 ± 74.5         101.2 ± 40.5 0.05
Albumin 3.3 ± 0.7 3.3 ± 0.4 0.99
INR 1.4 ± 0.3 1.2 ± 0.1 0.04
Creatinine 1.7 ± 2.1 1.1 ± 0.3 0.28
LDH  414 ± 52.7  399 ± 52.3 0.97
AFP 14.7 ± 15.8   698.4 ± 1391.1 0.13
ALT: Alanine transaminase; AST: Aspartate transaminase; GGT: Gamma 
glutamyl transpeptidase; INR: International normalized ratio; AP: Alkaline 
phosphatase; LDH: Lactate dehydrogenase; AFP: Alfa-fetoprotein.
Figure 1 Eight spots 
w­ere  d i f fe rent ia l ly 
ex­­pressed w­hen HCC 
samples w­ere comp­
ared w­ith non­HCC 
samples by proteomics 
analysis.
 P (HCC) = 1/(1 + e-z); in which z  = logit (P) = 7.877 
+ (0.37 × Apo-A1.2) – (1.54 × Apo-A4.1)
The receiver operating characteristic (ROC) curve 
for this equation using a cut-off  level of  0.35 showed an 
area under the ROC of  0.91; with an 89% sensitivity and 
a 91% specificity for diagnosis of  HCC (Figure 3).           
In order to define the real­ impact of  Apos in HCC, 
we calculated the risk of  HCC for different levels of  
Apo-A1 and a fixed l­evel­ of  Apo-A4 and vice versa. Risk 
curves are shown in Figure 4A-D. Figure 4A represents 
the risk of  HCC for different levels of  Apo-A1 (from 
its minimum level 0 to its maximum 20.3); adjusted 
for a fixed l­evel­ of  Apo-A4 (defined as its mean: 7.6). 
It reveals that the risk of  HCC increases following the 
increase in Apo-A1 level and it is higher than 50% when 
Apo-A1 > 11. Figure 4B represents the risk of  HCC for 
different levels of  Apo-A4 (from its minimum level 5 
to its maximum 15.3); and adjusted for a fixed l­evel­ of  
Apo-A1 (defined as its mean: 9.1). It is show­n that the 
risk of  HCC decreases following the increase in Apo-A1 
level. The risk of  HCC is less than 25% when Apo-A4 < 
8. Figure 4C shows the risk of  HCC for different levels 
of  Apo-A1, adjusted for a fixed l­evel­ of  Apo-A4 defined 
as its maximum in our study: 15.3. Interestingly, in this 
situation the risk of  HCC is very low (close to null) 
regardless of  Apo-A1 level. Finally, Figure 4D represents 
the risk of  HCC for different levels of  Apo-A1, adjusted 
for a fixed l­evel­ of  Apo-A4 defined as its minimum in 
our study: 5. As it is shown, the risk of  HCC is high (> 
60%) regardless of  Apo-A1 level. 
DISCUSSION
The increasing incidence and the poor prognosis of  pa-
tients w­ith HCC urge the identification of  tumor-specific 
markers for the early detection of  the disease and the 
discovery of  potential therapeutic targets. Considerable 
efforts are being extended toward development of  non-
invasive methods for HCC detection. The ideal biomarker 
for this type of  application should be detected with a high 
sensitivity in biological samples in a non-invasive manner; 
and blood represents the best source for detection of  
HCC related biomarkers.
Proteomics is a rapidly expanding discipline with a 
tremendous potential to extend our understanding of  
the molecular pathogenesis of  human diseases and to 
identify biomarkers improving patient diagnosis, treat-
ment, and prognosis. Hopefully, this knowledge will 
al­l­ow­ individual­ized approaches to patient care w­ith the 
devel­opment of  sel­ective treatment modal­ities to benefit 
the patients, however there are still some limitations 
that must be overcome before they are put into clinical 
applications. New analytical strategies are expected to 
increase our capability to detect target proteins with 
clinical impact. In this field, several approaches have 
recently been taken in order to simplify the analysis of  
serum proteins, including removal of  albumin and other 
high abundance proteins by affinity columns prior to 
analysis. This strategy provides gains in the number of  
lower abundance proteins, but it also results in the loss 
of  small proteins bound to albumin.
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Figure 2  Plasma levels of Apo­A1, Apo­A4 and Apo­E in controls and HCC patients. Apo-A4 was significantly higher in patients without HCC than in patients with 
HCC (2.1 ± 0.4 vs 1.4 ± 0.5; bP < 0.01).
Figure 3  ROC curve from the logistic equation. The AUROC is 0.91 with a 
cut-off level of 0.35; with an 89% sensitivity and a 91% specificity for diagnosis of 
HCC. 
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Figure 4  Risk curve of hepatocellular carcinoma for different values of one apolipoprotein and a fixed level of the other apolipoproteins. A: Risk of HCC for 
different Apo-A1 levels and fixed Apo-A4 level (mean); B: Risk of HCC for different Apo-A4 levels and fixed Apo-A1 level (mean); C: Risk of HCC for different Apo-A1 
levels and fixed Apo-A4 level (maximum); D: Risk of HCC for different Apo-A1 levels and fixed Apo-A4 level (minimum).
Complexity of  liver function hinders the development 
of  a laboratory test to evaluate each clinical situation. 
Hepatocarcinogenesis is a slow and multifactorial process 
that involves the progressive accumulation of  changes 
at the level of  gene and protein expression. Up to now, 
dissimilar profiles of  up- and down-regulated proteins 
have been reported; this discrepancy might result from 
the distinct etiol­ogy and differentiation of  the anal­yzed 
HCC. However, it may also suggest that HCC may pro-
gress through different pathways resulting in the mole-
cular heterogeneity denoted by proteomic studies. All 
these factors make the identification of  universal HCC 
biomarkers difficul­t. 
This study was aimed to identify plasma protein mar-
kers for HCC in cirrhotic patients. We compared the pro-
tein profil­es in pl­asma betw­een cirrhotic patients w­ith and 
without HCC. This analysis revealed that 3 proteins were 
differentially expressed: Apo-A1, Apo-A4 and Apo-E. 
Univariate analysis comparing patients with and 
without HCC showed no differences in AFP plasma 
concentration, whereas Apo-A4 was significantly higher 
in patients without HCC (2.1 ± 0.4 vs 1.4 ± 0.5; P < 
0.01). The multivariate analysis confirmed Apo-A4 and 
Apo-A1 as the only independent factors related to HCC 
risk. Apo-A1 is associated with a higher risk of  HCC, as 
against to Apo-A4 which is related to lower risk of  HCC, 
while AFP was not associated with risk of  HCC. The 
logistic equation from these data allows us to estimate the 
risk of  HCC for a single patient with an 89% sensitivity 
and a 91% specificity. Apo-A1 is associated w­ith higher 
risk of  HCC (OR 1.45; 95% CI: 1.11-1.89, P = 0.006). On 
the contrary, Apo-A4 is inversely correlated with HCC 
risk (OR 0.21; 95% CI: 0.09-0.50, P < 0.001), i.e. when its 
level is high, the risk of  HCC is very low independent of  
Apo-A1 levels. 
Metabolism and homeostasis of  carbohydrates, am-
ino acids and lipids depend on liver function. Most Apo, 
l­ipids and l­ipoproteins, are synthesized in the l­iver. Thus 
hepatocellular injury or chronic liver diseases including 
HCC may result in abnormal pattern of  these molecules 
in plasma[14]. The mechanisms leading to this alteration 
may be related to cytokines, metabolic cellular substances, 
or tumor factors, however they are not fully known. Pati-
ents with HCC frequently have other liver diseases such as 
chronic hepatitis and cirrhosis, which are often associated 
with plasma lipid and lipoprotein alterations[15]. Most Apos 
are synthesized in the l­iver[16] and some of  them have been 
identified as serum markers in different types of  cancer[17]. 
Furthermore, an Apo-A1 isoform has been identified as 
a pathological hallmark that may help understand the mol-
ecular pathogenesis of  HCC[18].
Plasma triglycerides concentration in HCC patients 
was compared with controls in several studies. It was 
found to be decreased in one study[19], while increased[20] 
or not significantl­y different[21] in other studies. These data 
emphasize the l­ack of  specificity of  these findings, so that 
the results must be interpreted with caution. Lipoprotein-a 
together with ferritin and AFP may be a sensitive marker 
of  liver function, since it has been found to increase in 
patients with acute hepatitis[22] and in those with HCC[23]. 
Liver is also the main organ for the synthesis, storage, 
transportation and degradation of  some Apo[24]. Each 
Apo may be influenced by liver disease in a different 
way. To date, few data have been reported concerning 
changes in Apo concentration related to liver diseases 
or HCC. Hyperexpression of  HBx in liver cells could 
inhibit Apo-B secretion[25]. Patients with metastatic liver 
cancer, showed an increase of  Apo-E levels during slight 
bile stagnation[21]. Apo-M mRNA l­evel­s w­ere significantl­y 
lower in HCC tissues than in the surrounding normal 
hepatic tissues. How­ever, these data have to be confirmed 
in further studies[26]. 
The identification of  biol­ogical­ targets l­eading to an 
early diagnosis of  HCC is considered a priority of  clinical 
hepatology. State of  the art technologies such as genomics 
and proteomics have opened new frontiers in modern 
biomedical research. The methodological breakthrough 
that has taken place within proteomics over the last decade 
creates a major impact on clinical practice by promoting 
new ways in disease diagnosis, treatment, and surveillance. 
It is expected that the discovery of  new biomarkers from 
differential­ protein/peptide profil­ing w­il­l­ benefit the cl­ini-
cal management of  HCC in the near future. However, the 
complexity of  HCC is still challenging for this still young 
science.
We compared protein profil­es of  cancerous and non-
cancerous plasma samples in order to identify new bio-
markers of  HCC. Two apolipoproteins were identified: 
Apo-A4 and Apo-A1, which may be considered as tumor 
markers. This may extend our knowledge of  the molecular 
pathogenesis of  HCC. These findings may have important 
implications for the screening for HCC, since Apo-A4 
and Apo-A1 may be used in combination with other 
traditional markers such as AFP, for an earlier and more 
efficient diagnosis of  this cancer. How­ever, further studies 
of  large cohorts of  patients are needed to determine their 
clinical use. Assessment of  the relationship between these 
biomarkers and specific features of  HCC such as size, 
presence of  vascular invasion or extrahepatic spread, may 
help determine their prognostic usefulness. Analysis of  
plasma and tissue samples from patients with HCC by 
proteomic and genomic approaches, may allow discovery 
of  potential targets for therapeutic intervention. 
Our resul­ts provide additional­ confirmation that pro-
teomic approaches can accurately identify HCC in pati-
ents with cirrhosis. These findings may have important 
implications for the screening and diagnosis of  the HCC. 
They al­so provide some val­uabl­e information to recognize 
changes in molecular pathways that might participate in 
HCC development. However, further studies of  large 
cohorts of  patients are needed in order to define their 
clinical use.
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tocellular carcinoma (HCC) is considered a priority of clinical hepatology. 
State of the art technologies such as genomics and proteomics have opened 
new frontiers in modern biomedical research. Protein profiles of cancerous 
and non-cancerous plasma samples can be compared in order to identify 
new biomarkers of HCC. Those markers may led to an earlier diagnosis and 
application of more effective therapeutic interventions, thus improving the HCC 
patients prognosis. 
Research frontiers
Although numerous biomarkers with potential diagnostic or prognostic 
significance for HCC have been identified, most of them have never reached 
general use, in part due to lack of availability of reagents, lack of reproducibility 
or lack of a good and clear system of development. There have been only two 
FDA-approved tumor markers until now [alpha fetoprotein (AFP) and AFP-L3]. 
Therefore, a standardized approach is required to assess tumor markers, and 
further studies in large patient cohorts and preferably from multiple centers 
are necessary. Proteins perform and regulate most biological functions. The 
systematic analysis of the whole proteome may provide a functional meaning 
to the information provided by genome expression studies. One of the most 
common applications of proteomics is the development of novel biomarkers of 
disease, particularly cancer. In spite of many recent technological advances 
in methods for the separation and analysis of proteins, two-dimensional gel 
electrophoresis is still the ‘‘gold standard’’ technique in this area.
Innovations and breakthroughs
The present study identified two apolipoproteins (Apo-A4 and Apo-A1) that are 
differentially expressed in HCC and non-tumor serum samples. Our results 
provide additional confirmation that proteomic approaches can accurately 
identify HCC in patients with cirrhosis. These findings may extend our 
knowledge of the molecular pathogenesis of HCC. Since two-dimensional 
gel electrophoresis is an expensive technology, most studies are based on 
a modest sample size, thus it is critical that the statistical power should be 
sufficient to detect protein expression differences of interest. Our findings 
have clear statistical significance and may have important clinical implications, 
since Apo-A4 and Apo-A1 may be used in combination with other traditional 
markers such as AFP for an earlier and more efficient diagnosis of liver cancer. 
However, further studies of large cohorts of patients are needed to determine 
their clinical use. 
Applications 
These findings may have important implications for the screening for HCC, 
since Apo-A4 and Apo-A1 may be used in combination with other traditional 
markers such as AFP, for an earlier and more efficient diagnosis of this cancer. 
They also provide valuable information for the investigation of the molecular 
pathways that might participate in HCC development. Assessment of the 
relationship between these biomarkers and specific features of HCC such as 
size, presence of vascular invasion or extrahepatic spread, may help determine 
their prognostic usefulness. Analysis of plasma and tissue samples from 
patients with HCC by proteomic and genomic approaches, may allow discovery 
of potential targets for therapeutic intervention. 
Peer review
The authors evaluated biomarkers of HCC using proteomic approach. 
Differential expression of plasma protein between patients with and without 
HCC was analyzed. The results of this study concluded that Apo-A4 and 
Apo-A1 may be used clinically as biomarkers of HCC with a high sensibility and 
specificity. This is an interesting study, and the results may be important to the 
clinical field. 
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